	TANSMITTAL LET	Case No. 10466/84								
Serial No.	TRADEMOG Date	Examiner	Group Art Unit							
09/904,786	July 12, 2001	To be assigned	1645							
Inventor(s)										
Ashkenazi et al.										
Title of Invention										
SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME										

SECILLI	SECRETED AND THANSMEMBRANE FORTER FIDES AND NOCCERC ACIDS ENCODING THE SAME												
TO THE COMMISSIONER FOR PATENTS													
Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); copy of Sequence Listing in computer readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and return postcard.													
	Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.												
	A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.												
	Petition for amonth extension of time.												
\boxtimes	No additional fee is required.												
	The fee has been calculated as shown below:												
	Other Than Small Entity Small Entity												
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Add'l Fee	or	Rate	Add'l Fee			
Total		Minus				x \$9=			x \$18=				
Indep.		Minus				x 42=		<u> </u>	x \$84=				
First Presentation of Multiple Dep. Claim]	+ \$140 =	ļ		+ \$280=				
						Total add'I fee	\$		Total add'I fee	\$			
	Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ A duplicate copy of this sheet is enclosed.												
	A check in the	amount of	\$ to cover the	he filing fee is	encl	osed.							
\boxtimes	The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.												
	I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.												
Respectfully submitted, Gregory M. Zinkl Ph.D. Registration No. 48,492 Agent for Applicant BRINKS HOFER GILSON & LIONE													
	X 10395												

CHICAGO, ILLINOIS 60610

(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no. EL 392680645US, with sufficient postage, in in envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on Commissioner for Patents.

Date: 61/25/02

rev. Dec.-00



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023
www.usdto.gov

APPLICATION NUMBER 09/904.786

O'C 3/2001

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

Avi Ashkenazi

P1618P2C47

CONFIRMATION NO. 3015

FORMALITIES LETTER

OC000000007162179

Paul E. Rauch, Ph.D.
Brinks, Hofer, Gilson & Lior
NBC Tower - Suite 3600
455 Cityfront Plaza Drive

Chicago, IL 60611-5599

Date Mailed: 12/06/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1 136(a).

A request to transfer the computer readable form from another application on file at the U.S. Patent and
Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be
complied with since there is no compliant CRF present at the United States Patent and Trademark Office.
Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a
statement that the content of the sequence listing information recorded in computer readable form is
identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new
matter, as required by 37 CFR 1 821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE